Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Porter

Showing results (151-160 of 199) with videos related to

Pageof 20
Sort By:
Blood Advances|October 4, 2017
Somatic HLA Mutations Expose the Role of Class I-Mediated Autoimmunity in Aplastic Anemia and its Clonal ComplicationsDaria V Babushok, Jamie L Duke, Hongbo M Xie, et al.
Blood Advances|January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy eraXin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
Blood|May 12, 2016
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapyVijay G Bhoj, Dimitrios Arhontoulis, Gerald Wertheim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromesBart L Scott, Marcelo C Pasquini, Brent R Logan, et al.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
JCO Precision Oncology|May 26, 2021
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic SyndromeLaura W Dillon, Gege Gui, Brent R Logan, et al.
Cancer Discovery|April 3, 2023
Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell-Intrinsic DysfunctionIn-Young Jung, Robert L Bartoszek, Andrew J Rech, et al.
Blood Advances|May 4, 2022
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Blood Advances|July 31, 2023
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphomaMichael Scordo, Jessica R Flynn, Mithat Gonen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2019
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual DiseaseChristopher S Hourigan, Laura W Dillon, Gege Gui, et al.
Pageof 20

Showing results (151-160 of 199) with videos related to

Sort By:
Pageof 20
Blood Advances|October 4, 2017
Somatic HLA Mutations Expose the Role of Class I-Mediated Autoimmunity in Aplastic Anemia and its Clonal ComplicationsDaria V Babushok, Jamie L Duke, Hongbo M Xie, et al.
Blood Advances|January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy eraXin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
Blood|May 12, 2016
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapyVijay G Bhoj, Dimitrios Arhontoulis, Gerald Wertheim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromesBart L Scott, Marcelo C Pasquini, Brent R Logan, et al.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
JCO Precision Oncology|May 26, 2021
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic SyndromeLaura W Dillon, Gege Gui, Brent R Logan, et al.
Cancer Discovery|April 3, 2023
Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell-Intrinsic DysfunctionIn-Young Jung, Robert L Bartoszek, Andrew J Rech, et al.
Blood Advances|May 4, 2022
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Blood Advances|July 31, 2023
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphomaMichael Scordo, Jessica R Flynn, Mithat Gonen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2019
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual DiseaseChristopher S Hourigan, Laura W Dillon, Gege Gui, et al.
Pageof 20